目的：探讨注射用利培酮微球治疗精神分裂症的疗效和安全性。方法将160例精神分裂症患者采用随机数字表法分为两组，每组80例，观察组予以肌内注射利培酮微球治疗，对照组口服利培酮片治疗，观察6个月。治疗前后采用阳性与阴性症状量表评定临床疗效，随时记录治疗过程中出现的不良反应。结果治疗6个月后两组阳性与阴性症状量表各因子及总分评分均较治疗前显著下降（P＜0．01），观察组评分显著低于对照组（P＜0．01）。观察组不良反应发生率为41．3％，对照组为63．8％，观察组显著低于对照组（ P＜0．01）。结论注射用利培酮微球治疗精神分裂患者疗效显著，安全性高，优于口服利培酮片剂治疗，值得临床推广应用。“,”Objective To explore the curative effect and safety of risperidone for depot suspension (RDS) in the treatment of schizophrenia .Methods A total of 160 schizophrenics were randomly divided into 2 groups of 80 ones each ,observation was treated with RDS ,and control group with oral risperidone tablets for 6 months .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS ) before and after treatment and adverse reactions recorded at any time during treatment .Results After 6 month treatment the each factor and total score of the PANSS of both groups lowered more significantly compared with pre‐treatment (P<0 .01) ,those were significantly lower in observation than in control group (P<0 .01) .The incidence of adverse reactions was respectively 41 .3% in observation and 63 .8% in control group ,the former significantly lower than the latter (P<0 .01) .Conclusion RDS has an evident effect and higher safety compared with single risperidone tablets in the treatment of schizophrenics ,deserves clinical generalization and application .